Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
380843-75-4
Purity
95%
Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile.
Properties
Name
Bosutinib
Smiles
COC=1C=C(NC=2C(C#N)=CN=C3C=C(OCCCN4CCN(C)CC4)C(OC)=CC23)C(Cl)=CC1Cl
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
SDS
KIN001-160 | bosulif | bosutinib | ski 606
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$37
2 mg
$39
5 mg
$41
10 mg
$43
15 mg
$45
20 mg
$48
25 mg
$53
30 mg
$55
35 mg
$58
40 mg
$60
45 mg
$63
50 mg
$65
75 mg
$68
100 mg
$POA
Quantity
1
Total amount
$ 41
KIN001-160 | bosulif | bosutinib | ski 606
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.
CAS:
0
CAS:2733145-45-2
0